BPC-157 vs TB-500
Verdict: These two are less rivals than teammates. BPC-157 is studied for localized, tissue-specific repair — tendons, ligaments, gut lining — with small daily doses. TB-500 works systemically through actin regulation and cell migration, dosed in milligrams once or twice a week. If forced to pick one for a specific tendon issue, community protocols usually start with BPC-157; for widespread soreness or slow general recovery, TB-500. In practice the most common protocol is both together.
Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| Typical dose | 250 mcg–500 mcg | 2 mg–5 mg |
| Frequency | 1–2x daily | 2x weekly (loading), then 1x weekly |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 5 mg, 10 mg | 5 mg, 10 mg |
| Typical mix | 5 mg + 2 ml water | 5 mg + 2.5 ml water |
| Units for typical dose | 10 units (250 mcg) | 125 units (2.5 mg) |
Mechanism: local signal vs systemic migration
BPC-157 is a stable gastric pentadecapeptide that appears to upregulate growth factor receptors and angiogenesis around damaged tissue — which is why protocols often inject it near the injury site. TB-500 is the active fragment of Thymosin Beta-4, a protein that regulates actin — the scaffolding cells use to move. That mechanism is inherently body-wide: it promotes cell migration to damage wherever it is, making injection site largely irrelevant.
Dosing rhythm is the practical difference
BPC-157 runs on a daily clock: 250–500 mcg one or two times per day, every day, typically for 4–8 weeks. TB-500 runs on a weekly clock: 2–5 mg split across one or two injections weekly, often front-loaded for the first month then dropped to maintenance. If daily injections are a dealbreaker for you, that alone decides this comparison.
Evidence profile
Both are research compounds without human approval. BPC-157 has a large body of rodent studies across tendon, muscle, nerve and GI models. TB-500's parent molecule Thymosin Beta-4 has been through human trials for cardiac and wound-healing indications, which gives its mechanism more human-adjacent data, though for the injected fragment itself the evidence remains preclinical.
Can you stack them?
The classic 'Wolverine stack' combines both: BPC-157 daily plus TB-500 weekly, covering the local and systemic repair pathways simultaneously. They are typically drawn as separate injections rather than mixed in one syringe unless reconstituted together deliberately.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.